You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A monoclonal antibody treatment from Eli Lilly may slow the progression of Alzheimer's disease, the New York Times reports.
In PLOS this week: potential neuropsychiatric drug targets identified, analysis of foodborne pathogen genome, and more.
The Helix Laboratory Platform is the first whole-exome sequencing platform to receive do novo authorization by the agency and paves the way for others.
Investigators identified five expression subtypes spanning three broader clusters in postmortem parahippocampal gyrus samples from Alzheimer's patients.
The bioinformatics and sequencing firm, formerly known as WuXi NextCode, will develop a population clinicogenomic database to support Emory's research.
In Science this week: CRISPR and expression-reported sequencing approach to trace genetic interactions, sample preparation platform for single-cell sequencing, and more.
An FDA advisory panel has determined there isn't enough data to gauge whether a new Alzheimer's disease drug works, according to NPR.
The APOE-ε4 allele, a major genetic risk factor for Alzheimer's disease, conveys more risk among Cuban than other Latino populations, the analysis found.
According to Stat News, US regulators appear to have a favorable view of Biogen's Alzheimer's disease therapy.
The Scientist reports a blood test for Alzheimer's disease is now available in many US states.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.
A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.
NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.
In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.